Screener / SEC EDGAR /CIK 0001818331 /10-K filed Feb 23, 2026, compared with Feb 20, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Health Services

GeneDx Holdings Corp. WGS

Compare with peers Embed
SEC comment letters, last 20 years

3 reviews of WGS's filings by SEC staff

UPLOAD and CORRESP
Reviews 3 latest letter Jun 18, 2025
Questions asked 27 each answered in the company's own letter
No closing letter 2 reviews without a letter saying the staff completed it

When the SEC's staff reviews a filing, it writes to the company with numbered questions, and the company answers each one in a letter. SEC publishes the exchange once the review is over, at least 20 business days later. A question is not an accusation; most reviews end with the company adding detail to its next filing.

How the reviews went

Every review on EDGAR, from the first staff letter to the letter that closes it

  1. 1. Staff letters 6 UPLOAD
  2. 2. Questions in them 27 numbered comments
  3. 3. Company replies 9 CORRESP
  4. 4. Reviews closed 1 of 3 closing letter

Half the closed reviews took 42 days or less from the first letter to the closing letter.

Form 10-K

2025-06-18 to 2025-07-30 · 1 question · 1 letter from the SEC, 1 from the company
Review closed 2025-07-30
RevenueSegments
Financial Statements · Note 14. Segment Reporting, page 20
SEC asked
We note that you have identified one reportable segment, GeneDX, and the CODM evaluates segment performance based on revenue and adjusted gross profit. We also note the reported segment revenue of GeneDX is consistent with consolidated revenue for the three months ended March 31, 2025.
Rest of the question

Please address the following: • If you have identified a single operating segment, tell us whether it is managed on a consolidated basis or other than consolidated basis, and fully explain how you reached that determination. If your single operating segment is managed on a consolidated basis, tell us how you determined adjusted gross profit, and not consolidated net income, is the measure required to be reported. In this regard, if the CODM uses more than one measure of a segment’s profit or loss in assessing segment performance and • 1. deciding how to allocate resources, the measure required to be reported is that which management believes is determined in accordance with the measurement principles most consistent with those used in measuring the corresponding amounts in the consolidated financial statements. See ASC 280-10-50-4, ASC 280-10-50-28A, and ASC 280-10-55-15D. • If you have identified multiple operating segments that have been aggregated into a single reportable segment, please describe each operating segment and revise your disclosure to indicate that operating segments have been aggregated. See ASC 280-10-50-21(a).

WGS answered
United States Securities and Exchange Commission

Division of Corporation Finance

Office of Industrial Applications and Services

100 F Street, N.E.

Washington, D.C. 20549

Attn: Tayyaba Shafique

Re: GeneDx Holdings Corp.

Form 10-K for Fiscal Year Ended December 31, 2024

Form 10-Q for Fiscal Quarter Ended March 31, 2025

File No. 001-39482

Ms. Shafique:

We are submitting this letter in response to comments from the staff of the Securities and Exchange Commission (the “SEC” or the “Staff”).
Rest of the answer

We received your letter dated June 18, 2025 (the “Comment Letter”), regarding the above-referenced filings of GeneDx Holdings Corp. (the “Company”). The headings and numbered paragraphs of this letter correspond to the headings and paragraph numbers contained in the Comment Letter. For ease of review, we have reproduced the text of the Staff’s comment in italics below, followed by the Company’s response.

Form 10-Q for Quarterly Period Ended March 31, 2025

Financial Statements

Note 14. Segment Reporting, page 20

We note that you have identified one reportable segment, GeneDx, and the CODM evaluates segment performance based on revenue and adjusted gross profit. We also note the reported segment revenue of GeneDx is consistent with consolidated revenue for the three months ended March 31, 2025. Please address the following:

•If you have identified a single operating segment, tell us whether it is managed on a consolidated basis or other than consolidated basis and fully explain how you reached that determination.

•If your single operating segment is managed on a consolidated basis, tell us how you determined adjusted gross profit, and not consolidated net income, is the measure required to be reported. In this regard, if the CODM uses more than one measure of a segment's profit or loss in assessing segment performance and deciding how to allocate resources, the measure required to be reported is that which management believes is determined in accordance with the measurement principles most consistent with those used in measuring the corresponding amounts in the consolidated financial statements. See ASC 280-10-50-4, ASC 280-10-50-28A, and ASC 280-10-55-15D.

•If you have identified multiple operating segments that have been aggregated into a single segment, please describe each operating segment and revise your disclosure to indicate that operating segments have been aggregated. See ASC 280-10-50-21(a).

The Company acknowledges the Staff’s comments and respectfully clarifies that during the periods covered by the Form 10-K for the Fiscal Year Ended December 31, 2024 and Form 10-Q for the Fiscal Quarter Ended March 31, 2025 (the “Relevant Reports”), the Company identified two operating segments: (i) GeneDx inclusive of Legacy GeneDx and Legacy Sema4 data revenues and associated costs (the “GeneDx operating segment”) and (ii) Legacy Sema4 diagnostics (the “Legacy Sema4 operating segment”).

Page | 1

The Legacy Sema4 operating segment, which offered reproductive and women’s health and somatic oncology diagnostic testing and screening products, is in the process of winding down its business activities. The Company’s Chief Operating Decision Maker (the “CODM”), its Chief Executive Officer, Katherine Stueland, continues to regularly review discrete financial information for the Legacy Sema4 operating segment in order to allocate resources to complete the wind down activities. The product offerings for the GeneDx operating segment, which include whole exome and whole genome tests, are fundamentally different from those of the Legacy Sema4 operating segment and serve a different group of patients. Therefore, the two operating segments are not aggregated into a single segment and were reported separately as “GeneDx” and “Other”, respectively, in the Relevant Reports.

Subsequent to the events disclosed in Note 15 to the condensed consolidated financial statements included in its Form 10-Q for the Fiscal Quarter Ended March 31, 2025, the Company completed its acquisition of Fabric Genomics, Inc. (“Fabric Genomics”) on May 7, 2025. The results of operations for this business from the date of acquisition will be included in the Company’s consolidated results beginning with its Quarterly Report for the Fiscal Quarter Ended June 30, 2025.

The Company has identified Fabric Genomics as an operating segment (the “Fabric Genomics operating segment”) in accordance with the guidance in ASC 280. Because the Fabric Genomics operating segment does not meet the quantitative thresholds outlined in ASC 280-10-50-12, it does not represent a reportable segment as of June 30, 2025. Accordingly, for segment disclosure purposes, the financial information of the Fabric Genomics operating segment will be combined with that of the Legacy Sema4 operating segment and disclosed in the “Other” category in the Company’s Quarterly Report for the Fiscal Quarter Ended June 30, 2025, in accordance with ASC 280-10-50-15. Consistent with that guidance, the Company also plans to disclose the sources of revenue included in the “Other” category.

Read in the reply
In its next report

First report after the company's reply of Jul 16, 2025: 10-Q filed Jul 29, 2025 ↗, against the 10-Q filed Apr 30, 2025 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Also in this review: closing letter, 2025-07-30

Schedule PREM14A

2021-06-02 to 2021-08-10 · 23 questions · 3 letters from the SEC, 4 from the company
No closing letter
AcquisitionsRisk factorsRevenueNon-GAAP measuresLiquidity and cashDebtCritical estimatesResults discussion (MD&A)
After reviewing your response to these comments, we may have additional comments. Sema4, page 29
SEC asked (1)
Please balance your disclosure in this section by indicating, if true, that Sema4 serves patients primarily in New York, California, Florida, Connecticut and New Jersey and briefly indicate the material regulatory requirements Sema4 would face in order to expand into other states and the additional need to establish test reimbursement rates from third party payors in those areas.
WGS answered
The Company advises the Staff that Mount Sinai Genomics, Inc. d/b/a Sema4 (“Sema4”) receives clinical samples from all fifty states and meets the regulatory requirements, including holding the relevant licensure, to receive and process samples from such states. For the year ended December 31, 2020 and the three months ended March 31, 2021, a substantial portion of Sema4’s diagnostic testing volume occurred in New York, California, Florida, Connecticut and New Jersey.
Rest of the answer

This concentration was driven in large part by testing volume from Sema4’s COVID-19 diagnostic testing services, a substantial portion of which occurred in the aforementioned states. Sema4 views its COVID-19 diagnostic testing services as a non-core business relative to its women’s health and oncology diagnostics solutions. Although Sema4 anticipates that COVID-19 testing will continue in the short term, Sema4 expects demand for these tests to decrease as a result of the vaccine roll out. Accordingly, Sema4 expects the concentration in these states will decrease in future periods as COVID-19 testing volume decreases.

The Company further advises the Staff that, when Sema4 has expanded into new markets, Sema4 has historically utilized market-based knowledge and experience, payer utilization data, along with current and previously established Medicare allowable rates, to determine and establish fair market test reimbursement rates from third party payors; however, as noted above, Sema4 is currently operating in all fifty states.

In response to the Staff’s comment, the disclosure on pages 29 and 218 in the Amended Proxy Statement has been revised to clarify that Sema4 operates across the United States. Note 1 to the audited financial statements of Sema4 on page F-8 of the Amended Proxy Statement has been revised to clarify that Sema4 serves patients and bills third party payors across the United States, with a substantial portion of its diagnostic testing volume occurring in the aforementioned states, and corresponding disclosure has been included in Note 1 to the unaudited financial statements of Sema4 on page F-44 of the Amended Proxy Statement.

Read in the reply
Summary of the Proxy Statement, page 29
SEC asked (2)
You state herein that Sema4 was formed in October 2015. Elsewhere in the document, i.e., pages 212, 237 and F-31, the date is June 2017. Please reconcile or revise accordingly.
WGS answered
The Company advises the Staff that Sema4 was formed in October 2015 and commenced operations in June 2017. The disclosure has been revised to clarify the references to Sema4’s formation and commencement of operations on pages 29, 219 and 245 of the Amended Proxy Statement and in Note 1 to Sema4’s audited financial statements on page F-8 of the Amended Proxy Statement, and corresponding disclosure has been included in Note 1 to the unaudited financial statements of Sema4 on page F-44 of the Amended Proxy Statement.
Read in the reply
Stable Free Cash Flow, Prudent Debt and Financial Visibility, page 38
SEC asked (3)
Please balance your disclosure in this section by indicating the negative free cash flows experienced by Sema4 in each of the last three fiscal years and by indicating the amount of Sema4’s Long-term debt, net of current portion as of the date of the most recent balance sheet for Sema4 included in your proxy statement.
Rest of the question

Our Sponsor, certain members of our Board and our officers have interests in the Business Combination, page 93

WGS answered
The disclosure on page 39 of the Amended Proxy Statement has been revised to indicate the negative free cash flows experienced by Sema4 in each of the last three fiscal years and the amount of Sema4’s long-term debt, net of current portion, as of its most recent balance sheet.

Our Sponsor, certain members of our Board and our officers have interests in the Business Combination, page 93
Read in the reply
Stable Free Cash Flow, Prudent Debt and Financial Visibility, page 38
SEC asked (4)
Please expand your discussion to disclose your sponsor's, officers' and directors' aggregate average investment per share. In addition, clarify that in addition to being at risk of losing their entire investment if the transaction is not approved, that as a result of your sponsor's, officers' and directors' significantly lower investment per share in their CM Life shares as compared to your public investors, the
Rest of the question

insiders could make a substantial profit after the initial business combination even if public investors experience substantial losses.

WGS answered
The disclosure on page 93 of the Amended Proxy Statement has been expanded to disclose (i) the aggregate average investment per share of the Initial Stockholders and (ii) that the Initial Stockholders could make a substantial profit after the initial business combination even if public investors experience substantial losses.

The proposed Amended and Restated Certificate of Incorporation designates the Court of Chancery of the State of Delaware, page 110
Read in the reply
The proposed Amended and Restated Certificate of Incorporation designates the Court of · Chancery of the State of Delaware, page 110
SEC asked (5)
Please revise this risk factor to disclose that there is also a risk that your exclusive forum provision may result in increased costs for investors to bring a claim.
WGS answered
The Company has revised its disclosure on page 110 of the Amended Proxy Statement to clarify that there is a risk that its exclusive forum provision may result in increased costs for investors to bring a claim.
Read in the reply
Unaudited Pro Forma Condensed Combined Financial Information, page 114
SEC asked (6)
Please expand your description on page 121 of adjustment 5(c) to the pro forma balance sheet to provide an explanation of your expected accounting for the Earn-Out Shares in the reverse recapitalization. For example, clarify whether the shares to be issued to stockholders are tied to future employment with the combined entity and if the awards will be accounted for as the issuance of share-based payments under ASC
Rest of the question

718.

WGS answered
In response to the Staff’s comment, the disclosure in Note 1 to the unaudited pro forma condensed combined financial information on page 120 of the Amended Proxy Statement has been revised to more fully describe the conditions under which Earn-Out Shares may be issued, and the expected accounting for such Earn-Out Shares.
Rest of the answer

The additional disclosure is intended to clarify that Earn-Out Shares issuable to Sema4 Stockholders are expected to be accounted for as contingent consideration and classified as a liability in accordance with ASC 805, whereas Earn-Out Shares issuable to Earn-Out Service Providers are expected to be accounted for as equity classified share-based compensation in accordance with ASC 718.

Read in the reply
Unaudited Pro Forma Condensed Combined Financial Information, page 114
SEC asked (7)
Please expand your description on page 121 of adjustment 5(d) to the pro forma balance sheet to explain the details of the “reassessment of the terms of the Public Warrants” and how it results in a reclassification to equity following the business combination.
WGS answered
In response to the Staff’s comment, the Company re-evaluated its accounting considerations for the terms of the Public Warrants and determined that the Public Warrants should remain classified as a liability. As such the disclosure in Note 5 to the unaudited pro forma condensed combined financial information on page 124 of the Amended Proxy Statement has been revised to remove the adjustment previously noted in such section.
Read in the reply
Background of the Business Combination, page 151
SEC asked (8)
With reference to the first full paragraph on page 152, please revise this section to describe all contacts with various parties during the evaluation by the company of potential business combinations. Please disclose the number of companies that were contacted, how the potential acquisition opportunities were identified, and the analysis and evaluation that was conducted with respect to each potential acquisition
Rest of the question

opportunity. To the extent that any preliminary proposals were submitted/received from eliminated targets, please disclose all material proposal terms, including transaction structure, valuation, and equity split distribution. Please also revise to disclose why this transaction is being recommended as opposed to any alternatives.

WGS answered
In response to the Staff’s comment, the Company has revised the disclosure on pages 154-155 of the Amended Proxy Statement to describe its contacts with various parties during the evaluation of potential business combinations and to disclose why this transaction is being recommended as opposed to any alternatives.
Read in the reply
Background of the Business Combination, page 151
SEC asked (9)
To the extent material, please identify the individuals who participated in the meetings and discussions described in this section. For example, please identify who participated in the virtual meeting to discuss the business combination held on January 14, 2021.
WGS answered
In response to the Staff’s comment, the Company has expanded the disclosure on pages 154-157 of the Amended Proxy Statement to identify the individuals who participated in the meetings and discussions described in the Background of the Business Combination section.
Read in the reply
CMLS Board of Directors' Reasons for the Approval of the Business Combination, page 154
SEC asked (10)
Please describe in greater detail all material analyses the board relied upon in evaluating the financial aspects of the business combination. If there were any analyses that did not support the fairness of the transaction, please include appropriate disclosure.
WGS answered
In response to the Staff’s comment, the Company has revised the disclosure on pages 160-161 of the Amended Proxy Statement to describe in greater detail the material analyses upon which the board relied in evaluating the financial aspects of the business combination.
Read in the reply
Certain Sema4 Projected Financial Information, page 156
SEC asked (11)
Please revise to describe the extent to which the financial projections provided by Sema4 factored into or supported your valuation. Please also explain how these projections were used by management. In this regard, clarify whether the projections were accepted or whether management or the Board made any adjustments to these projections and if so, describe such adjustments.
WGS answered
In response to the Staff’s comment, the Company has revised the disclosure on pages 160-161 of the Amended Proxy Statement to describe the extent to which and how management used the financial projections provided by Sema4.
Read in the reply
Sema4's Business · Regulatory Strategy and Managed Care, page 219
SEC asked (12)
We note your disclosure here that you are preparing to submit your WES/WTS for approval by the FDA by engaging in the studies needed to demonstrate clinical utility. Under the heading "Pre-Market Approval" on page 228, please disclose the studies that will be necessary to achieve FDA approval and the current status of such studies.
WGS answered
The disclosure on page 235 of the Amended Proxy Statement has been revised to disclose the studies for Sema4’s WES/WTS LDT tests that will be necessary to achieve FDA approval and the current status of such studies.
Read in the reply
Intellectual Property · Patents, page 225
SEC asked (13)
We note your disclosure that you have patent applications related to various aspects of your laboratory, analytic and business practices. Please revise to disclose the specific technologies to which such patent applications relate, the type of patent protection you are seeking, the expected expiration dates and the applicable jurisdictions.
WGS answered
The disclosure on page 232 of the Amended Proxy Statement has been revised to disclose the specific technologies to which Sema4’s patent applications relate, the type of patent protection that Sema4 is seeking, the expected expiration dates and the applicable jurisdictions of such patent applications.
Read in the reply
Sema4's Management's Discussion and Analysis, page 237 · Comparison of the Years Ended December 31, 2020, 2019 and 2018, page 243
SEC asked (14)
We note the disclosure on page 223 referring to the collaborations or other agreements with Sanofi, Janssen and Merus. Please disclose the significant terms of these agreements, quantify the impact thereof on your financial statements to date or clarify, if true, that no material impact has been recognized based on the relevant terms and conditions.
Rest of the question

It appears other revenue has been impacted to some extent therefrom as mentioned on page 244.

WGS answered
The Company advises the Staff that none of the Sanofi, Janssen and Merus relationships individually have had a material impact on Sema4’s historical consolidated results of operations. As disclosed in the Amended Proxy Statement on page 245, Sema4 derives the majority of its revenue from its diagnostics test solutions. Sema4 records its revenues from collaboration agreements, like its contracts with Sanofi, Janssen and Merus, as other revenue.
Rest of the answer

During the years ended December 31, 2019 and 2020 and the three months ended March 31, 2021, other revenue represented between approximately 2.0% to 2.5% of Sema4’s total revenues, with revenue recognized from the Sanofi, Janssen and Merus contracts representing a portion of such other revenue. Sema4’s agreement with Sanofi, which individually represented less than 1% of total revenue for each of the years ended December 31, 2019 and 2020 and the three months ended March 31, 20211, is the most significant of such agreements. Sema4 has concluded that the impact from these agreements is not quantitatively material to Sema4’s financial statements.

As a result, the Company respectfully submits that the current details disclosed in the Amended Proxy Statement regarding the contractual terms of these relationships is adequate. References to these relationships have been included in the Proxy Statement because these relationships demonstrate Sema4’s ability to develop strategic relationships with Biopharma partners. In response to the Staff’s comment, the disclosure on page 230 of the Amended Proxy Statement has been revised to clarify that these relationships have not had material impact on Sema4’s historical results.

Read in the reply
Critical Accounting Policies and Estimates, page 253
SEC asked (15)
We note the disclosure on page 222 that you offer "a suite of products, services, and solutions to our Biopharma customers. While each of these solutions can represent a standalone offering, we believe that our Biopharma partners can realize significant value when collaborating with our team to utilize a more integrated, end-to-end solution." Regarding the revenue recognition critical accounting policy on pages
Rest of the question

254255, in any instances when there is one contract with multiple elements and/or products, services and solutions purchased at the same time, revise to disclose how you identify the relevant performance obligations and whether you allocate the contract’s transaction price to each performance obligation on a relative standalone selling price basis.

WGS answered
The Company advises the Staff that the disclosure in Note 2 to Sema4’s audited financial statements on page F-15 of the Amended Proxy Statement states that the goods and services transferred to Sema4’s customers pursuant to collaboration service agreements generally comprise a single performance obligation on the basis that such goods and services are not distinct within the context of the contract.
Rest of the answer

That is because, in accordance with ASC 606, Revenue from Contracts with Customers, the goods and services are highly independent and interrelated such that Sema4 would not be able to fulfill its underlying promise to its customers by transferred each good or service independently.

Currently, Sema4 has no collaboration services agreements that contain multiple performance obligations. In response to the Staff’s comment, the disclosure on pages 229 and 268 of the Amended Proxy Statement has been revised to clarify that goods and services that Sema4 transfers to its customers pursuant to such agreements generally comprise a single performance obligation. Therefore, allocation of the contract’s transaction price is not applicable.

Read in the reply
Beneficial Ownership of Securities, page 286
SEC asked (16)
Please identify the natural persons that will be the beneficial owners of the shares held by Icahn School of Medicine at Mount Sinai.
WGS answered
The Company advises the Staff that the Mount Sinai Health System (“MSHS”) is a New York Not-for-Profit Corporation and the Icahn School of Medicine at Mount Sinai (“ISMMS”) is a New York Education Corporation. Both are charities exempt from taxes under section 501(c)(3) of the Internal Revenue Code. Their assets are dedicated to the charitable missions of the organizations. Accordingly, no natural persons are beneficial owners of shares of Sema4 held by the ISMMS.
Rest of the answer

The responsibility and authority for the voting and investment decisions with respect to the shares of Sema4 held by the ISMMS is vested in those persons who from time to time are the executive officers of the ISMMS under the oversight and direction of its board of directors and of its sole member, MSHS, at the applicable time. The Company does not believe that the disclosure of the names of these individuals would be meaningful to the Company’s stockholders; however, in response to the Staff’s comment, the disclosure on page 303 of the Amended Proxy Statement has been revised to clarify they nature of the governance and ownership structure of ISMMS.

Read in the reply
General
SEC asked (17)
Please include a form of proxy card marked as “preliminary” in your next amendment. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
WGS answered
In response to the Staff’s comment, the Company has included a form of proxy card marked as “preliminary” in the Amended Proxy Statement.
Read in the reply
Revised Preliminary Proxy Statement on Schedule 14A · Selected Historical Financial Information of the Company, page 44
SEC asked (1)
Please revise to provide the balance sheet information as of March 31, 2021 on page 45. Please label the first column presented on page 45. Finally, it appears that the amount of Cash and marketable securities held in trust account of $442,774 has been presented in thousands of U.S. dollars, but all other balance sheet amounts are whole U.S. dollars. Please revise accordingly.
WGS answered
The financial tables on page 45 of the of the Second Amended Proxy Statement have been updated to provide the missing information from the Balance Sheet Data and to rectify the discrepancy in dollar amounts.
Read in the reply
Selected Historical Financial Information of Sema4, page 47
SEC asked (2)
Please revise Total stockholders’ (deficit) equity of $521,044 at March 31, 2021 on page 48 to indicate a deficit, similar to the deficits at December 31, 2020 and 2019. Risk Factors, page 52
WGS answered
The Total stockholders’ (deficit) equity on page 48 of the Second Amended Proxy Statement has been updated to indicate a deficit.
Read in the reply
Selected Historical Financial Information of Sema4, page 47
SEC asked (3)
Please add a risk factor to disclose the material risks to unaffiliated investors presented by taking the company public through a merger rather than an underwritten offering. These risks could include the absence of due diligence conducted by an underwriter that would be subject to liability for any material misstatements or omissions in a registration statement.
Rest of the question

Our Sponsor, certain members of our Board and our officers have interests in the Business Combination, page 93

WGS answered
The Company has added a disclosure on page 97 of the Second Amended Proxy Statement to the effect that there are risks to unaffiliated investors presented by taking the target company public through a merger, rather than an underwritten offering, which include the absence of underwriter due diligence and other associated risks.

Our Sponsor, certain members of our Board and our officers have interests in the Business Combination, page 93
Read in the reply
Selected Historical Financial Information of Sema4, page 47
SEC asked (4)
We note your revisions in response to prior comment 4. Please further revise to disclose your sponsor's, officers' and directors' aggregate average investment per share and the aggregate dollar amount of what the sponsor and its affiliates have at risk that depends on completion of a business combination.
Rest of the question

In addition to the current value of securities held, please include loans extended, fees due, and out-of-pocket expenses for which the sponsor and its affiliates are awaiting reimbursement. Provide similar disclosure for the company’s officers and directors, if material.

WGS answered
In response to the Staff’s comment, the Company has revised its disclosure on pages 93 and 94 to include statements regarding the aggregate average investment per share and the aggregate dollar amount of what the Sponsor, officers and directors have at risk subject to the completion of the proposed business combination.
Rest of the answer

Additionally, the Company advises that there are no loans extended, fees due, or out-of-pocket expenses for which the Sponsor, its affiliates, officers or directors are awaiting reimbursement, and the Company has added in such disclosure on page 94 of the Second Amended Proxy Statement.

Read in the reply
Critical Accounting Policies and Estimates, page 267
SEC asked (5)
We have read your response to comment 15 in our letter dated June 2, 2021. Please confirm our understanding that for your diagnostic test revenue contracts that typically consist of a single performance obligation to deliver diagnostic testing services to the ordering facility or patient, allocation of the transaction price is also not applicable.
WGS answered
The Company confirms the Staff’s understanding that, for Sema4’s diagnostic test revenue contracts that typically consist of a single performance obligation to deliver diagnostic testing services to the ordering facility or patient, allocation of a transaction price is not applicable. As disclosed on page 267 of the Second Amended Proxy Statement, Sema4 recognizes revenue when test results are delivered to customers for an amount that reflects what Sema4 expects to collect in exchange for its services.

In response to the Staff’s comment, the disclosure on page 267 in the Second Amended Proxy
Rest of the answer

Statement has been revised to clarify that, in Sema4’s diagnostic test revenue contracts that include a single performance obligation to deliver diagnostic testing services to an ordering facility or patient, allocation of the transaction price is not applicable.

Read in the reply
After reviewing your response to this comment, we may have additional comments. Related Agreements, page 31
SEC asked
We note your disclosure in this section that the summary disclosure of the Related Agreements is qualified in its entirety by reference to the complete text of each of the Related Agreements and that the forms of the Forfeiture Agreement, Shareholder Lock-up Letter, Sponsor Support Agreement, and Subscription Agreement are attached hereto as Annexes C, D, and E, respectively.
Rest of the question

However, we do not see that you have included the Forfeiture Agreement, Shareholder Lock-up Letter and Sponsor Support Agreement as annexes in your preliminary proxy statement. Please include those agreements as annexes to your proxy statement and revise this section to refer to the correct annexes, or revise your disclosure as appropriate.

WGS answered
In response to the Staff’s comment, the Company has included the Forms of Forfeiture Agreement, Shareholder Lock-Up Letter and Sponsor Support Agreement as Annexes F, G and H respectively and revised the disclosure on page 31 to reflect this.
Read in the reply

Also in this review: company letter, Aug 10, 2021

Form S-1

2020-08-19 to 2020-08-28 · 3 questions · 2 letters from the SEC, 4 from the company
No closing letter
AcquisitionsRisk factors
SEC asked (1)
We note you disclose on pages 59 and 125 that "the federal courts shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act against us or any of our directors, officers, other employees or agents." Please state that there is uncertainty as to whether a court would enforce such provision and state that investors cannot waive compliance with the
Rest of the question

federal securities laws and the rules and regulations thereunder. In that regard, we note that Section 22 of the Securities Act created concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder.

WGS answered
The Company respectfully advises the Staff that the Company has revised the disclosure on pages 60 and 130 in response to the Staff’s comment.
Read in the reply
SEC asked (2)
Please expand your disclosure to clarify Casdin Capital's current and future role in connection with any acquisition strategy. In that regard, we note you disclose that you intend to draw upon "Casdin Capital's scientific process" as you evaluate targets, that Casdin Capital will provide you with "a pipeline of proprietary opportunities that will continue to increase as new players enter" and that you intend to
Rest of the question

leverage its "position as more than just an investor, but a key partner."

WGS answered
The Company respectfully advises the Staff that it has revised the disclosure on pages

6, 7, 81 and 82 to clarify Casdin Capital’s role in response to the Staff’s comment.
Read in the reply
SEC asked
We note your risk factor disclosure on page 56 discloses that your warrant agreement has an exclusive forum clause which shall be applicable to any action, proceeding or claim against you arising out of or relating in any way to the warrant agreement, including under the Securities Act, but that such provision will not apply to suits brought to enforce any liability or duty created by the Exchange Act.
Rest of the question

Please also ensure that the forum selection provision in Section 9.3 of your Form of Warrant Agreement filed as Exhibit 4.4 states this clearly, or tell us how you will inform investors in future filings that the provision applies to actions arising under the Securities Act, but not the Exchange Act.

WGS answered
The Company respectfully advises the Staff that it has revised Section 9.3 of Exhibit 4.4 to clearly state that such exclusive forum provision will not apply to suits brought to enforce any liability or duty created by the Exchange Act.
Read in the reply

Also in this review: company letter, Aug 28, 2020, company letter, Aug 28, 2020

Letters without questions

Other letters

UPLOAD and CORRESP
8 other letters: notices that a filing will not be reviewed, requests to declare a registration effective, and the like
  • Sep 2, 2022 · WGS: letter to the SEC · Sema4 Holdings Corp. Registration Statement on Form S-3 (File No. 333-267112) filed...
  • Sep 2, 2022 · WGS: letter to the SEC · Sema4 Holdings Corp. Registration Statement on Form S-3 (File No. 333-267108) filed...
  • Aug 31, 2022 · SEC: will not review the filing · Sema4 Holdings Corp. · Registration Statement on Form S-3 · Filed August 26, 2022 ·...
  • Aug 31, 2022 · SEC: will not review the filing · Sema4 Holdings Corp. · Registration Statement on Form S-3 · Filed August 26, 2022 ·...
  • May 9, 2022 · WGS: letter to the SEC · Sema4 Holdings Corp. - Registration Statement on Form S-1 (File No. 333-264626)
  • May 5, 2022 · SEC: will not review the filing · Sema4 Holdings Corp. · Registration Statement on Form S-1 · Filed May 3, 2022 · File...
  • Aug 10, 2021 · SEC: will not review the filing · Sema4 Holdings Corp. · Registration Statement on Form S-1 · Filed August 4, 2021 ·...
  • Jul 2, 2021 · SEC: review completed · CM Life Sciences, Inc. · Preliminary Merger Proxy Statement on Schedule 14A · Filed...

From the SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), 24 letters filed since 2020-08-19. Questions and answers are matched by their numbers; topics come from words in each question. The reports are compared word for word (same form, before the first SEC letter against the first report after the company's reply). No AI.

Sources

The SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), matched question by question. No AI.

Also

Filings: the letters in the filing list.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/WGS/export.csv") into a cell.

Next in Owners and insiders:Insider trades
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.